Maxim Group analyst Allen Klee maintains Trxade Health (NASDAQ:MEDS) with a Buy and lowers the price target from $2.5 to $1.75.
- Headlines
- Maxim Group Maintains Buy on Trxade Health, Lowers Price Target to $1.75
Maxim Group Maintains Buy on Trxade Health, Lowers Price Target to $1.75
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Latest
19:48
South Korea's Acting **** Sang-mook was indicted by the largest opposition party for “neglecting his duties”
19:47
Boehringer Ingelheim China and Shanghai Pharma Holdings have reached a Global Strategy cooperation.
19:45
The Gaza Strip health department: the current round of the Israeli-Palestinian conflict has resulted in 45,885 deaths in the Gaza Strip.